Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This Phase I study
will be conducted in HSV-seropositive subjects with advanced malignant solid tumors that are
refractory to conventional therapies. This is an open label study to determine the safety and
tolerability of VG161, and recommended dose of VG161 for Phase II trials.